Literature DB >> 10495422

Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ.

C Wassberg1, M Thörn, J Yuen, T Hakulinen, U Ringborg.   

Abstract

We calculated the short-term and long-term risks of developing cancer among 3,766 patients with a diagnosis of cutaneous melanoma in situ in Sweden from 1958 to 1992. In total, 393 patients developed a primary cancer at any site compared with an expected number of 177 [standardized incidence ratio (SIR) = 2.2, 95% confidence interval (CI) = 2.0-2.4]. Patients below 60 years of age at diagnosis had the highest SIR (2.7, 95% CI = 2.3-3.2). The overall risks were similar between men and women. The highest risk was seen during the first year of follow-up, though the risk remained elevated also after 15 or more years of follow-up. For specific sites, the highest SIR was found for developing invasive cutaneous malignant melanoma (SIR = 22.2). The risk of subsequent primary non-melanoma skin cancer was elevated 8-fold in men and almost 7-fold in women. An elevated risk was also found for female breast cancer (SIR = 1.4). Especially among women, other sites with increased cancer risk (though not significant) were non-Hodgkin's lymphoma (SIR = 1.9), multiple myeloma (3.2) and cancers of the colon (1.6) and pancreas (1.6). In conclusion, patients with melanoma in situ run a generally increased risk of developing primary cancers, especially cutaneous malignant melanoma and non-melanoma skin cancer. The increased long-term risk of cancer after diagnosis of melanoma in situ may be due to continuing carcinogenic exposure or to intrinsic tumor susceptibility. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10495422     DOI: 10.1002/(sici)1097-0215(19991029)83:3<314::aid-ijc5>3.0.co;2-9

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

2.  Increased risk of second primary cancers after a diagnosis of melanoma.

Authors:  Porcia T Bradford; D Michal Freedman; Alisa M Goldstein; Margaret A Tucker
Journal:  Arch Dermatol       Date:  2010-03

3.  A method for probing disease relatedness using common clinical eligibility criteria.

Authors:  Mary Regina Boland; Riccardo Miotto; Chunhua Weng
Journal:  Stud Health Technol Inform       Date:  2013

4.  Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017.

Authors:  Selin Tokez; Marlies Wakkee; Marieke Louwman; Eline Noels; Tamar Nijsten; Loes Hollestein
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

Review 5.  Cancer in veterinarians.

Authors:  L Fritschi
Journal:  Occup Environ Med       Date:  2000-05       Impact factor: 4.402

6.  Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients.

Authors:  Haike M J van der Velden; Michelle M van Rossum; Willeke A M Blokx; Jan B M Boezeman; Marie-Jeanne P Gerritsen
Journal:  Dermatol Res Pract       Date:  2009-12-31

7.  Risk of subsequent primary tumor development in melanoma patients.

Authors:  Veronika Tóth; Zsófia Hatvani; Beáta Somlai; Judit Hársing; János F László; Sarolta Kárpáti
Journal:  Pathol Oncol Res       Date:  2013-05-17       Impact factor: 3.201

8.  Host risk factors, ultraviolet index of residence, and incident malignant melanoma in situ among US women and men.

Authors:  Andrew C Walls; Jiali Han; Tricia Li; Abrar A Qureshi
Journal:  Am J Epidemiol       Date:  2013-04-11       Impact factor: 4.897

9.  Familial malignant melanoma - overview.

Authors:  Tadeusz Debniak
Journal:  Hered Cancer Clin Pract       Date:  2004-07-15       Impact factor: 2.857

10.  Association between melanocytic nevi and risk of breast diseases: The French E3N prospective cohort.

Authors:  Marina Kvaskoff; Anne Bijon; Sylvie Mesrine; Alice Vilier; Laura Baglietto; Agnès Fournier; Françoise Clavel-Chapelon; Laure Dossus; Marie-Christine Boutron-Ruault
Journal:  PLoS Med       Date:  2014-06-10       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.